H.C. Wainwright raised the firm’s price target on Nurix Therapeutics to $26 from $19 and keeps a Buy rating on the shares after Nurix presented updated clinical data from its orally available Bruton’s tyrosine kinase degrader, NX-5948, at the European Hematology Association annual meeting. Following the data, the firm raised its view on the probability of approval for NX-5948 to 50% from 30% previously, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Reports Promising NX-5948 Trial Results
- Nurix Therapeutics presents results from ongoing NX-5948 trial
- Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
- Nurix Therapeutics files automatic mixed securities shelf
- Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)